Identification and validation of cardiac nonconserved human-specific enhancers  

作　　者：Yawen Zhang Yiting Gui Xudong Chen Feng Wang Fang Wu Youhua Wang Xu Wang Yonghao Gui Qiang Li 

机构地区：[1]Translational Medical Center for Development and Disease,Shanghai Key Laboratory of Birth Defect,Institute of Pediatrics,Children's Hospital of Fudan University,National Children's Medical Center,Shanghai 201102,China [2]Cardiovascular Center,NHC Key Laboratory of Neonatal Diseases(Fudan University),Children's Hospital of Fudan University,National Children's Medical Center,Shanghai 201102,China [3]Department of Cardiology,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China [4]Cancer Institute,Fudan University Shanghai Cancer Center,Shanghai200032,China

出　　处：《Genes & Diseases》2023年第1期55-57,共3页基因与疾病（英文）

基　　金：This work was supported by The Natural Science Foundation of Shanghai(China)(No.21ZR1410100);The National Natural Science Foundation of China(No.81873481,81771632,81470442,81741081 and 81170147);The National Key Research and Development Program of China(No.2016YFC1000500);National Basic Research Program of China(973 Program)(No.2013CB945401);The Shanghai Key Laboratory of Birth Defects(China)(No.13DZ2260600).

摘　　要：Congenital heart disease(CHD)is one of the most common causes of neonatal mortality.The worldwide morbidity of CHD is 9.410%o,while the proportion of CHD patients who are reported to carry mutations in coding regions is<50%.Enhancers play an important role in the spatio-temporal expression of target genes,and a lot of related variations are associated with CHD.There are conserved and nonconserved enhancers.

关 键 词：MORTALITY CONSERVED NEONATAL 

分 类 号：R54[医药卫生—心血管疾病]